{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:24:46Z","timestamp":1784366686827,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T00:00:00Z","timestamp":1411171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00535-014-0998-z","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T07:01:36Z","timestamp":1411110096000},"page":"675-682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA"],"prefix":"10.1007","volume":"50","author":[{"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Hirohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuni","family":"Nakanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,20]]},"reference":[{"key":"998_CR1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291\u2013308.","journal-title":"Hepatology"},{"key":"998_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237\u201367.","journal-title":"J Hepatol"},{"issue":"Suppl S1","key":"998_CR3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hepr.12270","volume":"44","author":"Working Subgroup (English Version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis","year":"2014","unstructured":"Working Subgroup (English Version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis. The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res. 2014;44(Suppl S1):71\u201390.","journal-title":"Hepatol Res"},{"key":"998_CR4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2009.11.027","volume":"52","author":"R Poupon","year":"2010","unstructured":"Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol. 2010;52:745\u201358.","journal-title":"J Hepatol"},{"key":"998_CR5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871\u20137.","journal-title":"Hepatology"},{"key":"998_CR6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EM Kuiper","year":"2009","unstructured":"Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281\u20137.","journal-title":"Gastroenterology"},{"key":"998_CR7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715\u201320.","journal-title":"Gastroenterology"},{"key":"998_CR8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","volume":"43","author":"TM Willson","year":"2000","unstructured":"Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527\u201350.","journal-title":"J Med Chem"},{"key":"998_CR9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","volume":"16","author":"S Iwasaki","year":"1999","unstructured":"Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, et al. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res. 1999;16:12\u20138.","journal-title":"Hepatol Res"},{"key":"998_CR10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","volume":"44","author":"R Hazzan","year":"2010","unstructured":"Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2010;44:371\u20133.","journal-title":"J Clin Gastroenterol"},{"key":"998_CR11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","volume":"38","author":"T Kanda","year":"2003","unstructured":"Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38:573\u20138.","journal-title":"J Gastroenterol"},{"key":"998_CR12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","volume":"41","author":"R Kita","year":"2006","unstructured":"Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol. 2006;41:686\u201392.","journal-title":"J Gastroenterol"},{"key":"998_CR13","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","volume":"95","author":"T Kurihara","year":"2000","unstructured":"Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol. 2000;95:2990\u20132.","journal-title":"Am J Gastroenterol"},{"key":"998_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","volume":"34","author":"S Lens","year":"2014","unstructured":"Lens S, Leoz M, Nazal L, Bruguera M, Pares A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014;34:197\u2013203.","journal-title":"Liver Int"},{"key":"998_CR15","first-page":"1518","volume":"47","author":"S Miyaguchi","year":"2000","unstructured":"Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, et al. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology. 2000;47:1518\u201321.","journal-title":"Hepatogastroenterology"},{"key":"998_CR16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","volume":"95","author":"S Nakai","year":"2000","unstructured":"Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000;95:326\u20137.","journal-title":"Am J Gastroenterol"},{"key":"998_CR17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","volume":"21","author":"K Ohmoto","year":"2001","unstructured":"Ohmoto K, Mitsui Y, Yamamoto S. Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver. 2001;21:223\u20134.","journal-title":"Liver"},{"key":"998_CR18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00535-006-1778-1","volume":"41","author":"K Ohmoto","year":"2006","unstructured":"Ohmoto K, Yoshioka N, Yamamoto S. Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis. J Gastroenterol. 2006;41:502\u20133.","journal-title":"J Gastroenterol"},{"key":"998_CR19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","volume":"26","author":"Y Takeuchi","year":"2011","unstructured":"Takeuchi Y, Ikeda F, Fujioka S, Takaki T, Osawa T, Yasunaka T, et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol. 2011;26:1395\u2013401.","journal-title":"J Gastroenterol Hepatol"},{"key":"998_CR20","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","volume":"97","author":"K Yano","year":"2002","unstructured":"Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol. 2002;97:1075\u20137.","journal-title":"Am J Gastroenterol"},{"key":"998_CR21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","volume":"29","author":"J Itakura","year":"2004","unstructured":"Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res. 2004;29:216\u201322.","journal-title":"Hepatol Res"},{"key":"998_CR22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","volume":"38","author":"S Iwasaki","year":"2008","unstructured":"Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res. 2008;38:557\u201364.","journal-title":"Hepatol Res"},{"key":"998_CR23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/liv.12354","volume":"34","author":"P Invernizzi","year":"2014","unstructured":"Invernizzi P, Gershwin ME. New therapeutics in primary biliary cirrhosis: will there ever be light? Liver Int. 2014;34:167\u201370.","journal-title":"Liver Int"},{"key":"998_CR24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1386-6346(01)00148-6","volume":"22","author":"T Nakano","year":"2002","unstructured":"Nakano T, Inoue K, Hirohara J, Arita S, Higuchi K, Omata M, et al. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatol Res. 2002;22:250\u201360.","journal-title":"Hepatol Res"},{"key":"998_CR25","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/hep.26176","volume":"57","author":"K Harada","year":"2013","unstructured":"Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology. 2013;57:1942\u20139.","journal-title":"Hepatology"},{"key":"998_CR26","first-page":"16","volume":"110","author":"A Tanaka","year":"2013","unstructured":"Tanaka A. Management of PBC cases failing to respond to UDCA. Nihon Shokakibyo Gakkai Zasshi. 2013;110:16\u201321.","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"issue":"Suppl S1","key":"998_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hepr.12269","volume":"44","author":"Drafting Committee for Hepatitis Management Guidelines","year":"2014","unstructured":"Drafting Committee for Hepatitis Management Guidelines, Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44(Suppl S1):1\u201358.","journal-title":"Hepatol Res"},{"issue":"Suppl S1","key":"998_CR28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hepr.12272","volume":"44","author":"Drafting Committee for Hepatitis Management Guidelines","year":"2014","unstructured":"Drafting Committee for Hepatitis Management Guidelines, Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: a 2014 update for genotype 1. Hepatol Res. 2014;44(Suppl S1):59\u201370.","journal-title":"Hepatol Res"},{"key":"998_CR29","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","volume":"129","author":"HU Marschall","year":"2005","unstructured":"Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology. 2005;129:476\u201385.","journal-title":"Gastroenterology"},{"key":"998_CR30","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","volume":"57","author":"A Honda","year":"2013","unstructured":"Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57:1931\u201341.","journal-title":"Hepatology"},{"key":"998_CR31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","volume":"44","author":"N Azemoto","year":"2009","unstructured":"Azemoto N, Abe M, Murata Y, Hiasa Y, Hamada M, Matsuura B, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol. 2009;44:630\u20134.","journal-title":"J Gastroenterol"},{"key":"998_CR32","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361\u20137.","journal-title":"J Hepatol"},{"key":"998_CR33","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186\u201394.","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-014-0998-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-014-0998-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-014-0998-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T18:07:00Z","timestamp":1717351620000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-014-0998-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,20]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1007\/s00535-014-0998-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,20]]}}}